Adenylating enzymes in Mycobacterium tuberculosis as drug targets

Current Topics in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 766-796

  Duckworth, Benjamin P ^a   Nelson, Kathryn M ^a   Aldrich, Courtney C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adenylate forming; Adenylation; Bisubstrate inhibitor; Tuberculosis

Indexed keywords

4 AMINOSALICYL DERIVATIVE; 5' O[N(4 HYDROXYBENZOYL)SULFAMOYL]ADENOSINE; 5' O[N(DODECANOYL)SULFAMOYL]ADENOSINE; 5' O[N(SALICYL)SULFAMOYL]ADENOSINE; ACYLSULFAMIDE; ACYLUREA DERIVATIVE; ADENOSINE TRIPHOSPHATE; ADENYLATE FORMING ENZYME; ALPHA, ALPHA DIFLUORO DERIVATIVE; AMINO ACID TRANSFER RNA LIGASE; BACTERIAL ENZYME; BETA KETOSULFONAMIDE; BIRA; ENZYME INHIBITOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FATTY ACYL AMP LIGASE; GUAA; GUANINE; LONG CHAIN FATTY ACID COENZYME A LIGASE; MENAQUINONE; MENE; MSHC; NADE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NONRIBOSOMAL PEPTIDE SYNTHETASE; PANC; PANTOTHENIC ACID; SIDEROPHORE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINYLSULFONAMIDE;

ADENYLATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BIOTINYLATION; CELL ASSAY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME CONFORMATION; ENZYME DEGRADATION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME STRUCTURE; FATTY ACID METABOLISM; FLUORESCENCE POLARIZATION; FLUOROMETRY; HIGH THROUGHPUT SCREENING; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; LIPID METABOLISM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RESPIRATORY CHAIN; REVIEW; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

AMINO ACYL-TRNA SYNTHETASES; ANIMALS; ANTITUBERCULAR AGENTS; ENZYME INHIBITORS; HUMANS; LIGASES; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860289203     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799984571     Document Type: Review

References (163)

1. World Health Organization. Global tuberculosis control 2010. http://www.who.int/tb/publications/global_report/2010/en/index.html
2. 3rd.; Blanchard, J.S. The chemical biology of new drugs in the development for tuberculosis. Curr. Opin. Chem. Biol., 2010, 14, 456-466.
3. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis. Nature, 2011, 469, 483-490.
4. Aldrich, C.C.; Boshoff, H.I.; Remmel, R.P. Antitubercular Agents. In: Burgers Medicinal Chemistry, Drug Discovery, and Development, 7th ed. Rotella, D.; Abraham, D.J. Eds. Wiley: Hoboken, N. J. 2010; Vol. 7, pp. 713-812.
5. Jacobson, K.R.; Tierney, D.B.; Jeon, C.Y.; Mitnick, C.D.; Murray, M.B. Treatment outcomes among patients with extensively drugresistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis., 2010, 51, 6-14.
6. rd; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.; Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.; Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver, K.; Osborne, J.; Quail, M.A.; Rajandream, M.A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton, J.; Squares, R.; Squares, S.; Sulston, J.E.; Taylor, K.; Whitehead, S.; Barrell, B.G. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998, 393, 537-544.
7. Galagan, J.E.; Sisk, P.; Stolte, C.; Weiner, B.; Koehrsen, M.; Wymore, F.; Reddy, T.B.; Zucker, J.D.; Engels, R.; Gellesch, M.; Hubble, J.; Jin, H.; Larson, L.; Mao, M.; Nitzberg, M.; White, J.; Zachariah, Z.K.; Sherlock, G.; Ball, C.A.; Schoolnik, G.K. TB database 2010: overview and update. Tuberculosis (Edinb), 2010, 90, 225-235.
8. Chim, N.; Habel, J.E.; Johnston, J.M.; Krieger, I.; Miallau, L.; Sankaranarayanan, R.; Morse, R.P.; Bruning, J.; Swanson, S.; Kim, H.; Kim, C.Y.; Li, H.; Bulloch, E.M.; Payne, R.J.; Manos-Turvey, A.; Hung, L.W.; Baker, E.N.; Lott, J.S.; James, M.N.; Terwilliger, T.C.; Eisenberg, D.S.; Sacchettini, J.C.; Goulding, C.W. The TB structural genomics consortium: a decade of progress. Tuberculosis (Edinb), 2011, 91, 155-172.
9. Lew, J.M.; Kapopoulou, A.; Jones, L.M.; Cole, S.T. TubercuList- 10 years after. Tuberculosis (Edinb) 2011, 91, 1-7.
10. Gulick, A.M. Conformational dynamics in the Acyl-CoA synthetases, adenylation domains of non-ribosomal peptide synthetases, and firefly luciferase. ACS Chem. Biol. 2009, 4, 811-827.
11. Schmelz, S.; Naismith, J.H. Adenylate-forming enzymes. Curr. Opin. Struct. Biol., 2009, 19, 666-671.
12. Hill, J.M.; Yu, G.; Shue, Y.-K.; Zydowsky, T.M.; Rebek, J. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents. U.S. Patent 5,726,195, March 10, 1998.
13. Schimmel, P.; Tao, J.; Hill, J. Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J., 1998, 12, 1599-1609.
14. Kim, S.; Lee, S.W.; Choi, E.C.; Choi, S.Y. Aminoacyl-tRNA synthetases and their inhibitors as a novel family of antibiotics. Appl. Microbiol. Biotechnol., 2003, 61, 278-288.
15. Jencks, W.P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA, 1981, 78, 4046-4050.
16. Pope, A.J.; Lapointe, J.; Mensah, L.; Benson, N.; Brown, M.J.; Moore, K.J. Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. I: Kinetic mechanism of the substrate activation reaction studied by transient and steady-state techniques. J. Biol. Chem., 1998, 273, 31680-31690.
17. Southgate, C.C.; Dixon, H.B. Phosphonate analogues of aminoacyl adenylates. Biochem. J., 1978, 175, 461-465.
18. Ueda, H.S., Y.; Hayashi, N.; Mitsunaga, J.; In, Y.; Doi, M.; Inoue, M.; Ishida, M. X-ray crystallographic conformational study of 5'- O-[N-(L-alanyl)-sulfamoyl]adenosine: A substrate analogue for alanyl-tRNA synthetase. Biochim. Biophys. Acta, 1991, 1080, 126-134.
19. Brown, M.J.; Mensah, L.M.; Doyle, M.L.; Broom, N.J.; Osbourne, N.; Forrest, A.K.; Richardson, C.M.; O'Hanlon, P.J.; Pope, A.J. Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry, 2000, 39, 6003-6011.
20. Isono, K.; Uramoto, M.; Kusakabe, H.; Miyata, N.; Koyama, H.; Ubukata, M.; Sethi, S.K.; McCloskey, J.A. Ascamycin and dealanylascamycin, nucleoside antibiotics from Streptomyces sp. J. Antibiot., 1984, 37, 670-672.
21. Copeland, R.A., Enzymes, A Practical Introduction to Structure, Mechanism, and Data Analysis, 2nd ed.; Wiley-VCH, New York, 2000.
22. Moshinsky, D.J.; Ruslim, L.; Blake, R.A.; Tang, F. A widely applicable, high-throughput TR-FRET assay for the measurement of kinase autophosphorylation: VEGFR-2 as a prototype. J. Biomol. Screen., 2003, 8, 447-452.
23. Bays, N.W.; Hill, A.D.; Kariv, I. A simplified scintillation proximity assay for fatty acid synthase activity: development and comparison with other FAS activity assays. J. Biomol Screen., 2009, 14, 636-642.
24. Vasan, M.; Neres, J.; Williams, J.; Wilson, D.J.; Teitelbaum, A.M.; Remmel, R.P.; Aldrich, C.C. Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by highthroughput screening. ChemMedChem, 2010, 5, 2079-2087.
25. Gaudet, E.A.; Huang, K.S.; Zhang, Y.; Huang, W.; Mark, D.; Sportsman, J.R. A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J. Biom. Screen., 2003, 8, 164-175.
26. Zhang, J.H.; Chung, T.D.Y.; Oldenbug, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen., 1999, 4, 67-73.
27. Ciulli, A.; Abell, C. Fragment-based approaches to enzyme inhibition. Curr. Opin. Biotechnol., 2007, 18, 489-496.
28. Murray, C.W.; Verdonk, M.L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput. Aided Mol. Des., 2002, 16, 741-753.
29. Erlanson, D.A. Fragment-based lead discovery: a chemical update. Curr. Opin. Biotechnol., 2006, 17, 643-652.
30. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today, 2004, 9, 430-431.
31. Lo, M.C.; Aulabaugh, A.; Jin, G.; Cowling, R.; Bard, J.; Malamas, M.; Ellestad, G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem., 2004, 332, 153-159.
32. Neumann, T.; Junker, H.D.; Schmidt, K.; Sekul, R. SPR-based fragment screening: advantages and applications. Curr. Top. Med. Chem., 2007, 7, 1630-1642.
33. Shuker, S.B.; Hajduk, P.J.; Meadows, R.P.; Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science, 1996, 274, 1531-1534.
34. Blundell, T.L.; Jhoti, H.; Abell, C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov., 2002, 1, 45-54.
35. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed., 1999, 38, 1784-1788.
36. Hung, A.W.; Silvestre, H.L.; Wen, S.; Ciulli, A.; Blundell, T.L.; Abell, C. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed., 2009, 48, 8452-8456.
37. Carr, R.; Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discov. Today, 2002, 7, 522-527.
38. Hurdle, J.G.; O'Neill, A.J.; Chopra, I. Prospects for aminoacyltRNA synthetase inhibitors as new antimicrobial agents. Antimicrob. Agents Chemother., 2005, 49, 4821-4833.
39. Chain, E.B.; Mellows, G. Pseudomonic acid. Part 1. The structure of pseudomonic acid A, a novel antibiotic produced by Pseudomonas fluorescens. J. Chem. Soc., Perkin Trans., 1 1977, 294-309.
40. Sassanfar, M.; Kranz, J.E.; Gallant, P.; Schimmel, P.; Shiba, K. A eubacterial Mycobacterium tuberculosis tRNA synthetase is eukaryote-like and resistant to a eubacterial-specific antisynthetase drug. Biochemistry, 1996, 35, 9995-10003.
41. Heacock, D.; Forsyth, C.J.; Shiba, K.; Musier-Forsyth, K. Synthesis and aminoacyl-tRNA synthetase inhibitory activity of prolyl adenylate analogs. Bioorg. Chem., 1996, 24, 273-289.
42. Lee, J.; Kang, S.U.; Kang, M.K.; Chun, M.W.; Jo, Y.J.; Kwak, J.H.; Kim, S. Methionyl adenylate analogues as inhibitors of methionyl-tRNA synthetase. Bioorg. Med. Chem. Lett., 1999, 9, 1365-1370.
43. Ingvarsson, H.; Jones, T.A.; Unge, T. Crystallization of Mycobacterium smegmatis methionyl-tRNA synthetase in the presence of methionine and adenosine. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2009, 65, 618-620.
44. Critchley, I.A.; Ochsner, U.A. Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839. Curr. Opin. Chem. Biol., 2008, 12, 409-417.
45. Dhiman, R.K.; Mahapatra, S.; Slayden, R.A.; Boyne, M.E.; Lenaerts, A.; Hinshaw, J.C.; Angala, S.K.; Chatterjee, D.; Biswas, K.; Narayanasamy, P.; Kurosu, M.; Crick, D.C. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol. Microbiol., 2009, 72, 85-97.
46. Rao, S.P.; Alonso, S.; Rand, L.; Dick, T.; Pethe, K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2008, 105, 11945-11950.
47. Sassetti, C.M.; Boyd, D.H.; Rubin, E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol., 2003, 48, 77-84.
48. Meganathan, R. Biosynthesis of menaquinone (vitamin K2) and ubiquinone (coenzyme Q): a perspective on enzymatic mechanisms. Vitam. Horm., 2001, 61, 173-218.
49. Collins, M.D.; Pirouz, T.; Goodfellow, M.; Minnikin, D.E. Distribution of menaquinones in actinomycetes and corynebacteria. J. Gen. Microbiol., 1977, 100, 221-230.
50. Holsclaw, C.M.; Sogi, K.M.; Gilmore, S.A.; Schelle, M.W.; Leavell, M.D.; Bertozzi, C.R.; Leary, J.A. Structural characterization of a novel sulfated menaquinone produced by stf3 from Mycobacterium tuberculosis. ACS Chem. Biol., 2008, 3, 619-624.
51. Tian, Y.; Suk, D.H.; Cai, F.; Crich, D.; Mesecar, A.D. Bacillus anthracis o-succinylbenzoyl-CoA synthetase: reaction kinetics and a novel inhibitor mimicking its reaction intermediate. Biochemistry, 2008, 47, 12434-12447.
52. Reger, A.S.; Wu, R.; Dunaway-Mariano, D.; Gulick, A.M. Structural characterization of a 140 degrees domain movement in the two-step reaction catalyzed by 4-chlorobenzoate:CoA ligase. Biochemistry, 2008, 47, 8016-8025.
53. Wu, R.; Cao, J.; Lu, X.; Reger, A.S.; Gulick, A.M.; Dunaway-Mariano, D. Mechanism of 4-chlorobenzoate:coenzyme a ligase catalysis. Biochemistry 2008, 47, 8026-8039.
54. Kwon, O.; Bhattacharyya, D.K.; Meganathan, R. Menaquinone (vitamin K2) biosynthesis: overexpression, purification, and properties of o-succinylbenzoyl-coenzyme A synthetase from Escherichia coli. J. Bacteriol., 1996, 178, 6778-6781.
55. Meganathan, R.; Bentley, R. Menaquinone (vitamin K2) biosynthesis: conversion of o-succinylbenzoic acid to 1,4- dihydroxy-2-naphthoic acid by Mycobacterium phlei enzymes. J. Bacteriol., 1979, 140, 92-98.
56. Gokhale, R.S.; Saxena, P.; Chopra, T.; Mohanty, D. Versatile polyketide enzymatic machinery for the biosynthesis of complex mycobacterial lipids. Nat. Prod. Rep., 2007, 24, 267-277.
57. Onwueme, K.C.; Vos, C.J.; Zurita, J.; Ferreras, J.A.; Quadri, L.E. The dimycocerosate ester polyketide virulence factors of mycobacteria. Prog. Lipid Res., 2005, 44, 259-302.
58. Takayama, K.; Wang, C.; Besra, G.S. Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev., 2005, 18, 81-101.
59. 3rd. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature, 2004, 431, 84-87.
60. McKinney, J.D.; Honer zu Bentrup, K.; Munoz-Elias, E.J.; Miczak, A.; Chen, B.; Chan, W.T.; Swenson, D.; Sacchettini, J.C.; Jacobs, W.R., Jr.; Russell, D.G. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 2000, 406, 735-738.
61. Timm, J.; Post, F.A.; Bekker, L.G.; Walther, G.B.; Wainwright, H.C.; Manganelli, R.; Chan, W.T.; Tsenova, L.; Gold, B.; Smith, I.; Kaplan, G.; McKinney, J.D. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc. Natl. Acad. Sci. USA, 2003, 100, 14321-14326.
62. Pandey, A.K.; Sassetti, C.M. Mycobacterial persistence requires the utilization of host cholesterol. Proc. Natl. Acad. Sci. USA, 2008, 105, 4376-4380.
63. Trivedi, O.A.; Arora, P.; Sridharan, V.; Tickoo, R.; Mohanty, D.; Gokhale, R.S. Enzymatic activation and transfer of fatty acids as acyl-adenylates in mycobacteria. Nature, 2004, 428, 441-445.
64. Arora, P.; Vats, A.; Saxena, P.; Mohanty, D.; Gokhale, R.S. Promiscuous fatty acyl CoA ligases produce acyl-CoA and acyl- SNAC precursors for polyketide biosynthesis. J. Am. Chem. Soc., 2005, 127, 9388-9389.
65. Dam, T.; Danelishvili, L.; Wu, M.; Bermudez, L.E. The fadD2 gene is required for efficient Mycobacterium avium invasion of mucosal epithelial cells. J. Infect. Dis., 2006, 193, 1135-1142.
66. Van der Geize, R.; Yam, K.; Heuser, T.; Wilbrink, M.H.; Hara, H.; Anderton, M.C.; Sim, E.; Dijkhuizen, L.; Davies, J.E.; Mohn, W.W.; Eltis, L.D. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc. Natl. Acad. Sci. USA, 2007, 104, 1947-1952.
67. Wilbrink, M.H.; Petrusma, M.; Dijkhuizen, L.; van der Geize, R. FadD19 of Rhodococcus rhodochrous DSM43269, a steroidcoenzyme A ligase essential for degradation of C-24 branched sterol side chains. Appl. Environ. Microbiol., 2011, 77, 4455-4464.
68. Khare, G.; Gupta, V.; Gupta, R.K.; Gupta, R.; Bhat, R.; Tyagi, A.K. Dissecting the role of critical residues and substrate preference of a fatty acyl-CoA synthetase (FadD13) of Mycobacterium tuberculosis. PLoS One, 2009, 4, e8387.
69. Ferreras, J.A.; Stirrett, K.L.; Lu, X.; Ryu, J.S.; Soll, C.E.; Tan, D.S.; Quadri, L.E. Mycobacterial phenolic glycolipid virulence factor biosynthesis: mechanism and small-molecule inhibition of polyketide chain initiation. Chem. Biol., 2008, 15, 51-61.
70. He, W.; Soll, C.E.; Chavadi, S.S.; Zhang, G.; Warren, J.D.; Quadri, L.E. Cooperation between a coenzyme A-independent stand-alone initiation module and an iterative type I polyketide synthase during synthesis of mycobacterial phenolic glycolipids. J. Am. Chem. Soc., 2009, 131, 16744-16750.
71. Camacho, L.R.; Constant, P.; Raynaud, C.; Laneelle, M.A.; Triccas, J.A.; Gicquel, B.; Daffe, M.; Guilhot, C. Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis. Evidence that this lipid is involved in the cell wall permeability barrier. J. Biol. Chem., 2001, 276, 19845-19854.
72. Infante, E.; Aguilar, L.D.; Gicquel, B.; Pando, R.H. Immunogenicity and protective efficacy of the Mycobacterium tuberculosis fadD26 mutant. Clin. Exp. Immunol., 2005, 141, 21-28.
73. Sirakova, T.D.; Fitzmaurice, A.M.; Kolattukudy, P. Regulation of expression of mas and fadD28, two genes involved in production of dimycocerosyl phthiocerol, a virulence factor of Mycobacterium tuberculosis. J. Bacteriol., 2002, 184, 6796-6802.
74. Trivedi, O.A.; Arora, P.; Vats, A.; Ansari, M.Z.; Tickoo, R.; Sridharan, V.; Mohanty, D.; Gokhale, R.S. Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid. Mol. Cell, 2005, 17, 631-643.
75. Leger, M.; Gavalda, S.; Guillet, V.; van der Rest, B.; Slama, N.; Montrozier, H.; Mourey, L.; Quemard, A.; Daffe, M.; Marrakchi, H. The dual function of the Mycobacterium tuberculosis FadD32 required for mycolic acid biosynthesis. Chem. Biol., 2009, 16, 510-519.
76. Gavalda, S.; Leger, M.; van der Rest, B.; Stella, A.; Bardou, F.; Montrozier, H.; Chalut, C.; Burlet-Schiltz, O.; Marrakchi, H.; Daffe, M.; Quemard, A. The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis. J. Biol. Chem., 2009, 284, 19255-19264.
77. Portevin, D.; de Sousa-D'Auria, C.; Montrozier, H.; Houssin, C.; Stella, A.; Laneelle, M.A.; Bardou, F.; Guilhot, C.; Daffe, M. The acyl-AMP ligase FadD32 and AccD4-containing acyl-CoA carboxylase are required for the synthesis of mycolic acids and essential for mycobacterial growth: identification of the carboxylation product and determination of the acyl-CoA carboxylase components. J. Biol. Chem., 2005, 280, 8862-8874.
78. Carroll, P.; Faray-Kele, M.C.; Parish, T. Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl. Environ. Microbiol., 2011, 77, 5040-5043.
79. Krithika, R.; Marathe, U.; Saxena, P.; Ansari, M.Z.; Mohanty, D.; Gokhale, R.S. A genetic locus required for iron acquisition in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2006, 103, 2069-2074.
80. Rindi, L.; Fattorini, L.; Bonanni, D.; Iona, E.; Freer, G.; Tan, D.; Deho, G.; Orefici, G.; Garzelli, C. Involvement of the fadD33 gene in the growth of Mycobacterium tuberculosis in the liver of BALB/c mice. Microbiology, 2002, 148, 3873-3880.
81. Rindi, L.; Bonanni, D.; Lari, N.; Garzelli, C. Requirement of gene fadD33 for the growth of Mycobacterium tuberculosis in a hepatocyte cell line. New. Microbiol., 2004, 27, 125-131.
82. Buchholz, T.J.; Geders, T.W.; Bartley, F.E., 3rd; Reynolds, K.A.; Smith, J.L.; Sherman, D.H. Structural basis for binding specificity between subclasses of modular polyketide synthase docking domains. ACS Chem. Biol., 2009, 4, 41-52.
83. Arora, P.; Goyal, A.; Natarajan, V.T.; Rajakumara, E.; Verma, P.; Gupta, R.; Yousuf, M.; Trivedi, O.A.; Mohanty, D.; Tyagi, A.; Sankaranarayanan, R.; Gokhale, R.S. Mechanistic and functional insights into fatty acid activation in Mycobacterium tuberculosis. Nat. Chem. Biol., 2009, 5, 166-173.
84. Grimes, K.D.; Aldrich, C.C. A high-throughput screening fluorescence polarization assay for fatty acid adenylating enzymes in Mycobacterium tuberculosis. Anal. Biochem., 2011, 417, 264-273.
85. Ratledge, C.; Dover, L.G. Iron metabolism in pathogenic bacteria. Annu. Rev. Microbiol., 2000, 54, 881-941.
86. Quadri, L.E. Assembly of aryl-capped siderophores by modular peptide synthetases and polyketide synthases. Mol. Microbiol., 2000, 37, 1-12.
87. Gobin, J.; Moore, C.H.; Reeve, J.R., Jr.; Wong, D.K.; Gibson, B.W.; Horwitz, M.A. Iron acquisition by Mycobacterium tuberculosis: isolation and characterization of a family of iron-binding exochelins. Proc. Natl. Acad. Sci. USA, 1995, 92, 5189-5193.
88. Snow, G.A. Isolation and structure of mycobactin-T, a growth factor of Mycobacterium tuberculosis. Biochem. J., 1965, 97, 166-175.
89. Snow, G.A. Mycobactins: iron-chelating growth factors from mycobacteria. Bacteriol. Rev., 1970, 34, 99-125.
90. Vergne, A.F.; Walz, A.J.; Miller, M.J. Iron chelators from mycobacteria (1954-1999) and potential therapeutic applications. Nat. Prod. Rep., 2000, 17, 99-116.
91. Quadri, L.E.; Sello, J.; Keating, T.A.; Weinreb, P.H.; Walsh, C.T. Identification of a Mycobacterium tuberculosis gene cluster encoding the biosynthetic enzymes for assembly of the virulenceconferring siderophore mycobactin. Chem. Biol., 1998, 5, 631-645.
92. Chavadi, S.S.; Stirrett, K.L.; Edupuganti, U.R.; Vergnolle, O.; Sadhanandan, G.; Marchiano, E.; Martin, C.; Qiu, W.G.; Soll, C.E.; Quadri, L.E. Mutational and phylogenetic analyses of the mycobacterial mbt gene cluster. J. Bacteriol., 2011, 193, 5905-5913.
93. Moody, D.B.; Young, D.C.; Cheng, T.Y.; Rosat, J.P.; Roura-Mir, C.; O'Connor, P.B.; Zajonc, D.M.; Walz, A.; Miller, M.J.; Levery, S.B.; Wilson, I.A.; Costello, C.E.; Brenner, M.B. T cell activation by lipopeptide antigens. Science, 2004, 303, 527-531.
94. De Voss, J.J.; Rutter, K.; Schroeder, B.G.; Su, H.; Zhu, Y.; Barry, C.E., 3rd The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc. Natl. Acad. Sci. USA, 2000, 97, 1252-1257.
95. Luo, M.; Fadeev, E.A.; Groves, J.T. Mycobactin-mediated iron acquisition within macrophages. Nat. Chem. Biol., 2005, 1, 149-153.
96. Murray, M.J.; Murray, A.B.; Murray, M.B.; Murray, C.J. The adverse effect of iron repletion on the course of certain infections. Br. Med. J., 1978, 2, 1113-1115.
97. Manabe, Y.C.; Saviola, B.J.; Sun, L.; Murphy, J.R.; Bishai, W.R. Attenuation of virulence in Mycobacterium tuberculosis expressing a constitutively active iron repressor. Proc. Natl. Acad. Sci. USA, 1999, 96, 12844-12848.
98. Sikora, A.L.; Wilson, D.J.; Aldrich, C.C.; Blanchard, J.S. Kinetic and inhibition studies of dihydroxybenzoate-AMP ligase from Escherichia coli. Biochemistry, 2010, 49, 3648-3657.
99. May, J.J.; Kessler, N.; Marahiel, M.A.; Stubbs, M.T. Crystal structure of DhbE, an archetype for aryl acid activating domains of modular nonribosomal peptide synthetases. Proc. Natl. Acad. Sci. USA, 2002, 99, 12120-12125.
100. Drake, E.J.; Duckworth, B.P.; Neres, J.; Aldrich, C.C.; Gulick, A.M. Biochemical and structural characterization of bisubstrate inhibitors of BasE, the self-standing nonribosomal peptide synthetase adenylate-forming enzyme of acinetobactin synthesis. Biochemistry, 2010, 49, 9292-9305.
101. Ferreras, J.A.; Ryu, J.S.; Di Lello, F.; Tan, D.S.; Quadri, L.E. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat. Chem. Biol., 2005, 1, 29-32.
102. Somu, R.V.; Boshoff, H.; Qiao, C.; Bennett, E.M.; Barry, C.E., 3rd; Aldrich, C.C. Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J. Med. Chem., 2006, 49, 31-34.
103. Miethke, M.; Bisseret, P.; Beckering, C.L.; Vignard, D.; Eustache, J.; Marahiel, M.A. Inhibition of aryl acid adenylation domains involved in bacterial siderophore synthesis. FEBS. J., 2006, 273, 409-419.
104. Neres, J.; Labello, N.P.; Somu, R.V.; Boshoff, H.I.; Wilson, D.J.; Vannada, J.; Chen, L.; Barry, C.E., 3rd; Bennett, E.M.; Aldrich, C.C. Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structureactivity relationships of the nucleobase domain of 5'-O-[N- (salicyl)sulfamoyl]adenosine. J. Med. Chem., 2008, 51, 5349-5370.
105. Qiao, C.H.; Gupte, A.; Boshoff, H.I.; Wilson, D.J.; Bennett, E.M.; Somu, R.V.; Barry, C.E., 3rd; Aldrich, C.C. 5'-O-[(N-Acyl) sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: An adenylation enzyme required for siderophore biosynthesis of the mycobactins. J. Med. Chem., 2007, 50, 6080-6094.
106. Gupte, A.; Boshoff, H.I.; Wilson, D.J.; Neres, J.; Labello, N.P.; Somu, R.V.; Xing, C.; Barry, C.E., 3rd; Aldrich, C.C. Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'- O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis. J. Med. Chem., 2008, 51, 7495-7507.
107. Vannada, J.; Bennett, E.M.; Wilson, D.J.; Boshoff, H.I.; Barry, C.E., 3rd; Aldrich, C.C. Design, synthesis, and biological evaluation of bketosulfonamide adenylation inhibitors as potential antitubercular agents. Org. Lett., 2006, 8, 4707-4710.
108. Qiao, C.H.; Wilson, D.J.; Bennett, E.M.; Aldrich, C.C. A mechanism-based aryl carrier protein/thiolation domain affinity probe. J. Am. Chem. Soc., 2007, 129, 6350-6351.
109. Labello, N.P.; Bennett, E.M.; Ferguson, D.M.; Aldrich, C.C. Quantitative three dimensional structure linear interaction energy model of 5'-O-[N-(salicyl)sulfamoyl]adenosine and the aryl acid adenylating enzyme MbtA. J. Med. Chem., 2008, 51, 7154-7160.
110. Somu, R.V.; Wilson, D.J.; Bennett, E.M.; Boshoff, H.I.; Celia, L.; Beck, B.J.; Barry, C.E., 3rd; Aldrich, C.C. Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J. Med. Chem., 2006, 49, 7623-7635.
111. Braibant, M.; Gilot, P.; Content, J. The ATP-binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol. Rev., 2000, 24, 449-467.
112. Niederweis, M. Mycobacterial porins - new channel proteins in unique outer membranes. Mol. Microbiol., 2003, 49, 1167-1177.
113. Neres, J.; Wilson, D.J.; Celia, L.; Beck, B.J.; Aldrich, C.C. Aryl acid adenylating enzymes involved in siderophore biosynthesis: fluorescence polarization assay, ligand specificity, and discovery of non-nucleoside inhibitors via high-throughput screening. Biochemistry, 2008, 47, 11735-11749.
114. unpublished results, João Neres, Courtney Aldrich.
115. Belenky, P.; Bogan, K.L.; Brenner, C. NAD+ metabolism in health and disease. Trends Biochem. Sci., 2007, 32, 12-19.
116. Lin, H. Nicotinamide adenine dinucleotide: beyond a redox coenzyme. Org. Biomol. Chem., 2007, 5, 2541-2554.
117. rd Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J. Biol. Chem., 2008, 283, 19329-19341.
118. LaRonde-LeBlanc, N.; Resto, M.; Gerratana, B. Regulation of active site coupling in glutamine-dependent NAD(+) synthetase. Nat. Struct. Mol. Biol., 2009, 16, 421-429.
119. Rizzi, M.; Bolognesi, M.; Coda, A. A novel deamido-NAD+- binding site revealed by the trapped NAD-adenylate intermediate in the NAD+ synthetase structure. Structure, 1998, 6, 1129-1140.
120. Velu, S.E.; Cristofoli, W.A.; Garcia, G.J.; Brouillette, C.G.; Pierson, M.C.; Luan, C.H.; DeLucas, L.J.; Brouillette, W.J. Tethered dimers as NAD synthetase inhibitors with antibacterial activity. J. Med. Chem., 2003, 46, 3371-3381.
121. Velu, S.E.; Luan, C.H.; Delucas, L.J.; Brouillette, C.G.; Brouillette, W.J. Tethered dimer inhibitors of NAD synthetase: parallel synthesis of an aryl-substituted SAR library. J. Comb. Chem., 2005, 7, 898-904.
122. Moro, W.B.; Yang, Z.; Kane, T.A.; Brouillette, C.G.; Brouillette, W.J. Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs). Bioorg. Med. Chem. Lett., 2009, 19, 2001-2005.
123. Moro, W.B.; Yang, Z.; Kane, T.A.; Zhou, Q.; Harville, S.; Brouillette, C.G.; Brouillette, W.J. SAR Studies for a New Class of Antibacterial NAD Biosynthesis Inhibitors. J. Comb. Chem., 2009, 11(4),617-625.
124. Hyde, J.E. Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr. Drug Targets, 2007, 8, 31-47.
125. Hatfull, G.; Jacobs, W.R. Jr. Molecular Genetics of Mycobacteria, American Society for Microbiology: Washington D. C., 2000.
126. Fukuyama, T.T. Formation of an adenyl xanthosine monophosphate intermediate by xanthosine 5'-phosphate aminase and its inhibition by psicofuranine. J. Biol. Chem., 1966, 241, 4745-4749.
127. Zyk, N.; Citri, N.; Moyed, H.S. Conformative response of xanthosine 5'-phosphate aminase. Biochemistry, 1969, 8, 2787-2794.
128. Patel, N.; Moyed, H.S.; Kane, J.F. Xanthosine-5'-phosphate amidotransferase from Escherichia coli. J. Biol. Chem., 1975, 250, 2609-2613.
129. von der Saal, W.; Crysler, C.S.; Villafranca, J.J. Positional isotope exchange and kinetic experiments with Escherichia coli guanosine- 5'-monophosphate synthetase. Biochemistry, 1985, 24, 5343-5350.
130. Sakamoto, N.; Hatfield, G.W.; Moyed, H.S. Physical properties and subunit structure of xanthosine 5'-phosphate aminase. J. Biol. Chem., 1972, 247, 5880-5887.
131. Tesmer, J.J.; Klem, T.J.; Deras, M.L.; Davisson, V.J.; Smith, J.L. The crystal structure of GMP synthetase reveals a novel catalytic triad and is a structural paradigm for two enzyme families. Nat. Struct. Biol., 1996, 3, 74-86.
132. Chittur, S.V.; Klem, T.J.; Shafer, C.M.; Davisson, V.J. Mechanism for acivicin inactivation of triad glutamine amidotransferases. Biochemistry, 2001, 40, 876-887.
133. Deras, M.L.; Chittur, S.V.; Davisson, V.J. N2-hydroxyguanosine 5'-monophosphate is a time-dependent inhibitor of Escherichia coli guanosine monophosphate synthetase. Biochemistry, 1999, 38, 303-310.
134. Moyed, H.S.; Magasanik, B. Enzymes essential for the biosynthesis of nucleic acid guanine; xanthosine 5'-phosphate aminase of Aerobacter aerogenes. J. Biol. Chem., 1957, 226, 351-363.
135. Fukuyama, T.T.; Donovan, K.L. Mechanism of hydroxylamine inhibition of xanthosine 5'-phosphate aminase. J. Biol. Chem., 1968, 243, 5798-5801.
136. Webb, M.E.; Smith, A.G.; Abell, C. Biosynthesis of pantothenate. Nat. Prod. Rep., 2004, 21, 695-721.
137. Sambandamurthy, V.K.; Wang, X.; Chen, B.; Russell, R.G.; Derrick, S.; Collins, F.M.; Morris, S.L.; Jacobs, W.R. Jr. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med., 2002, 8, 1171-1174.
138. Sambandamurthy, V.K.; Derrick, S.C.; Jalapathy, K.V.; Chen, B.; Russell, R.G.; Morris, S.L.; Jacobs, W.R. Jr. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun., 2005, 73, 1196-1203.
139. Zheng, R.; Blanchard, J.S. Steady-state and pre-steady-state kinetic analysis of Mycobacterium tuberculosis pantothenate synthetase. Biochemistry, 2001, 40, 12904-12912.
140. Zheng, R.; Dam, T.K.; Brewer, C.F.; Blanchard, J.S. Active site residues in Mycobacterium tuberculosis pantothenate synthetase required in the formation and stabilization of the adenylate intermediate. Biochemistry, 2004, 43, 7171-7178.
141. Wang, S.; Eisenberg, D. Crystal structures of a pantothenate synthetase from M. tuberculosis and its complexes with substrates and a reaction intermediate. Protein Sci., 2003, 12, 1097-1108.
142. Wang, S.; Eisenberg, D. Crystal structure of the pantothenate synthetase from Mycobacterium tuberculosis, snapshots of the enzyme in action. Biochemistry 2006, 45, 1554-1561.
143. White, E.L.; Southworth, K.; Ross, L.; Cooley, S.; Gill, R.B.; Sosa, M.I.; Manouvakhova, A.; Rasmussen, L.; Goulding, C.; Eisenberg, D.; Fletcher, T.M., 3rd A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J. Biomol. Screen., 2007, 12, 100-105.
144. Mycobacterium tuberculosis Pantothenate Synthetase Assay, NIH BioAssay. http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=375.
145. Velaparthi, S.; Brunsteiner, M.; Uddin, R.; Wan, B.; Franzblau, S.G.; Petukhov, P.A. 5-tert-butyl-N-pyrazol-4-yl-4,5,6,7- tetrahydrobenzo[d]isoxazole-3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: initiating a quest for new antitubercular drugs. J. Med. Chem., 2008, 51, 1999-2002.
146. Ciulli, A.; Scott, D.E.; Ando, M.; Reyes, F.; Saldanha, S.A.; Tuck, K.L.; Chirgadze, D.Y.; Blundell, T.L.; Abell, C. Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate. Chembiochem, 2008, 9, 2606-2611.
147. Tuck, K.L.; Saldanha, S.A.; Birch, L.M.; Smith, A.G.; Abell, C. The design and synthesis of inhibitors of pantothenate synthetase. Org. Biomol. Chem., 2006, 4, 3598-3610.
148. Newton, G.L.; Buchmeier, N.; Fahey, R.C. Biosynthesis and functions of mycothiol, the unique protective thiol of Actinobacteria. Microbiol. Mol. Biol. Rev., 2008, 72, 471-494.
149. Fan, F.; Vetting, M.W.; Frantom, P.A.; Blanchard, J.S. Structures and mechanisms of the mycothiol biosynthetic enzymes. Curr. Opin. Chem. Biol., 2009, 13, 451-459.
150. Sareen, D.; Newton, G.L.; Fahey, R.C.; Buchmeier, N.A. Mycothiol is essential for growth of Mycobacterium tuberculosis Erdman. J. Bacteriol., 2003, 185, 6736-6740.
151. Vilcheze, C.; Av-Gay, Y.; Attarian, R.; Liu, Z.; Hazbon, M.H.; Colangeli, R.; Chen, B.; Liu, W.; Alland, D.; Sacchettini, J.C.; Jacobs, W.R., Jr. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol. Microbiol., 2008, 69, 1316-1329.
152. Fan, F.; Luxenburger, A.; Painter, G.F.; Blanchard, J.S. Steady-state and pre-steady-state kinetic analysis of Mycobacterium smegmatis cysteine ligase (MshC). Biochemistry, 2007, 46, 11421-11429.
153. Tremblay, L.W.; Fan, F.; Vetting, M.W.; Blanchard, J.S. The 1.6 A crystal structure of Mycobacterium smegmatis MshC: the penultimate enzyme in the mycothiol biosynthetic pathway. Biochemistry, 2008, 47, 13326-13335.
154. Gutierrez-Lugo, M.T.; Bewley, C.A. Susceptibility and mode of binding of the Mycobacterium tuberculosis cysteinyl transferase mycothiol ligase to tRNA synthetase inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 2480-2483.
155. Fahey, R.C.; Newton, G.L.; Ta, P.V.; Buchmeier, N. Inhibitors of MshC and homologs thereof, and methods of identifying same. WO 2008/036139, March 27, 2008.
156. Newton, G.L.; Buchmeier, N.; La Clair, J.J.; Fahey, R.C. Evaluation of NTF1836 as an inhibitor of the mycothiol biosynthetic enzyme MshC in growing and non-replicating Mycobacterium tuberculosis. Bioorg. Med. Chem., 2011, 19, 3956-3964.
157. Gutierrez-Lugo, M.T.; Baker, H.; Shiloach, J.; Boshoff, H.; Bewley, C.A. Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening. J. Biomol. Screen, 2009, 14, 643-652.
158. Slayden, R.A.; Lee, R.E.; Barry, C.E., 3rd Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol. Microbiol., 2000, 38, 514-525.
159. Gago, G.; Kurth, D.; Diacovich, L.; Tsai, S.C.; Gramajo, H. Biochemical and structural characterization of an essential acyl coenzyme A carboxylase from Mycobacterium tuberculosis. J. Bacteriol., 2006, 188, 477-486.
160. Purushothaman, S.; Gupta, G.; Srivastava, R.; Ramu, V.G.; Surolia, A. Ligand specificity of group I biotin protein ligase of Mycobacterium tuberculosis. PLoS One, 2008, 3, e2320.
161. Brown, P.H.; Cronan, J.E.; Grotli, M.; Beckett, D. The biotin repressor: modulation of allostery by corepressor analogs. J. Mol. Biol., 2004, 337, 857-869.
162. Brown, P.H.; Beckett, D. Use of binding enthalpy to drive an allosteric transition. Biochemistry, 2005, 44, 3112-3121.
163. rd; Schnappinger, D.; Finzel, B.C.; Aldrich, C.C. Inhibition of biotin protein ligase from Mycobacterium tuberculosis. Chem. Biol., 2011, 18, 1432-1441.